Bolt Biotherapeutics Q4 2024 loss from ops $16.9M; cash $70.2M; BDC-4182 starts trial Q2 2025

Bolt Biotherapeutics, Inc.

Q4 2024 loss from operations $16.9M vs $19.8M in Q4 2023; full-year loss $73.0M vs $76.2M.
Collaboration revenue Q4 $7.7M (up from $2.1M Q4 2023); full year $7.7M (down from $7.9M).
Cash $70.2M expected to fund key milestones and operations through mid-2026.
BDC-4182 on track to start Phase 1 trial in gastric cancer in Q2 2025.
BDC-3042 Phase 1 fully enrolled at highest dose; no DLTs; data update expected Q2 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.